Analyst Brandon Folkes from H.C. Wainwright maintained a Buy rating on Heron Therapeutics and keeping the price target at $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Folkes has given his Buy rating due to a combination of factors surrounding Heron Therapeutics. The company’s recent capital restructuring is viewed positively as it provides the necessary flexibility for the continued growth of its key products, Zynrelef and Aponvie. Despite some temporary disruptions due to the transition to the vial access needle (VAN), the company remains on track with its revenue guidance, suggesting a strong potential for future growth.
Heron Therapeutics has shown promising signs with increased unit demand for both Zynrelef and Aponvie, supported by the launch of dedicated sales teams. The anticipated completion of the VAN transition and the introduction of expanded commercial initiatives are expected to drive further growth. Additionally, the granting of a permanent J-code for Zynrelef is likely to enhance reimbursement processes, setting the stage for improved financial performance. These strategic moves and the potential for significant revenue growth underpin Folkes’s optimistic outlook on Heron Therapeutics.
Folkes covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, Omeros, and Milestone Pharmaceuticals. According to TipRanks, Folkes has an average return of -6.3% and a 33.46% success rate on recommended stocks.